公开(公告)号：US20070292893A1

公开(公告)日：2007-12-20

申请号：US11837899

申请日：2007-08-13

Applicant: Paul Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/53 ,  G01N33/567

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

公开(公告)号：US20070254315A1

公开(公告)日：2007-11-01

申请号：US11760668

申请日：2007-06-08

Applicant: Paul Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/566 ,  G01N33/567

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

Abstract translation: 公开了筛选神经障碍的方法。 具体地，公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地，通过确定获得的组织样品中的β-N-甲基氨基-L-丙氨酸（BMAA）的水平，公开了用于诊断受试者的神经障碍或预测受试者发展神经障碍的可能性的方法 从主题。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制，治疗或预防神经障碍的方法。

公开(公告)号：US20050042686A1

公开(公告)日：2005-02-24

申请号：US10731411

申请日：2003-12-08

Applicant: Paul Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/53 ,  G01N33/566 ,  G01N33/567 ,  G01N33/68 ,  G01N33/94

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

Abstract translation: 公开了筛选神经障碍的方法。 具体地，公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地，通过确定获得的组织样品中的β-N-甲基氨基-L-丙氨酸（BMAA）的水平，公开了用于诊断受试者的神经障碍或预测受试者发展神经障碍的可能性的方法 从主题。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制，治疗或预防神经障碍的方法。

公开(公告)号：US07901895B2

公开(公告)日：2011-03-08

申请号：US11837899

申请日：2007-08-13

Applicant: Paul A Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul A Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/48 ,  G01N33/02 ,  G01N33/18 ,  G01N33/53 ,  C12Q1/04

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

Abstract translation: 公开了筛选神经障碍的方法。 具体地，公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地，通过确定组织样品中的B-甲基氨基-L-丙氨酸（BMAA）的水平，公开了用于诊断受试者神经障碍或预测受试者发展神经障碍的可能性的方法 从主题获得。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制，治疗或预防神经障碍的方法。

公开(公告)号：US07670783B2

公开(公告)日：2010-03-02

申请号：US11760668

申请日：2007-06-08

Applicant: Paul A Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul A Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/48 ,  G01N33/50

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

Abstract translation: 公开了筛选神经障碍的方法。 具体地，公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地，通过确定组织样品中的B-甲基氨基-L-丙氨酸（BMAA）的水平，公开了用于诊断受试者神经障碍或预测受试者发展神经障碍的可能性的方法 从主题获得。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制，治疗或预防神经障碍的方法。

公开(公告)号：US08541184B2

公开(公告)日：2013-09-24

申请号：US13015288

申请日：2011-01-27

Applicant: Paul Alan Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul Alan Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

Abstract translation: 公开了筛选神经障碍的方法。 具体地，公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地，通过确定获得的组织样品中的β-N-甲基氨基-L-丙氨酸（BMAA）的水平，公开了用于诊断受试者的神经障碍或预测受试者发展神经障碍的可能性的方法 从主题。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制，治疗或预防神经障碍的方法。